SCHEMBL18352140

SCHEMBL18352140

COc1ccc2c(c1)SCCO2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
HTT P42858 1/20 0.47
CTNNB1 P35222 3/20 0.43
WNT3A P56704 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPT P10636 2/20 0.43
HPGD P15428 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
GAA P10253 1/20 0.43
ALOX12 P18054 1/20 0.43
RYR2 Q92736 6/20 0.43
KCNH2 Q12809 1/20 0.43
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
SNCA P37840 1/20 0.40
LMNA P02545 2/20 0.39
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15979752 0.78 CTNNB1 (0.73) CTNNB1WNT3AALDH1A1MAPTHPGD
SCHEMBL3329915 0.77 CTNNB1 (0.47) CTNNB1WNT3AALDH1A1MAPTNPC1
SCHEMBL15979751 0.76 CTNNB1 (0.72) CTNNB1WNT3ASMN1; SMN2ALDH1A1MAPT
SCHEMBL10512084 0.74 MAOB (0.50) KDM4EHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL21382913 0.74 CTNNB1 (0.43) CTNNB1WNT3A
SCHEMBL21780862 0.74 MAOB (0.65) CTNNB1WNT3ASMN1; SMN2ALDH1A1HPGD
SCHEMBL745193 0.74 PKM (0.54) KDM4EHTTCTNNB1WNT3ASMN1; SMN2
SCHEMBL30627606 0.74 PKM (0.54) KDM4EHTTCTNNB1WNT3ASMN1; SMN2
SCHEMBL21382764 0.73 CTNNB1 (0.58) KDM4ECTNNB1WNT3ASMN1; SMN2ALDH1A1
SCHEMBL20786544 0.73 MAPT (0.47) KDM4ECTNNB1WNT3ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11673885-B2 γ-diketones as Wnt/β-catenin signaling pathway activators BIOSPLICE THERAPEUTICS, INC. (US) 2023-06-13 US disclosed
US-9951053-B2 γ-diketones as Wnt/β-catenin signaling pathway activators SAMUMED, LLC (US) 2018-04-24 US disclosed
US-20170260176-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS MED-PATHWAYS II LIMITED (VG) 2017-09-14 US disclosed
US-9533976-B2 γ-diketones as WNT/β-catenin signaling pathway activators SAMUMED, LLC (US) 2017-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170260176-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3A, GSK3B, WNT1 KDM4E 3701/4885HTT 2107/4885CTNNB1 6/4885
US-11673885-B2 γ-diketones as Wnt/β-catenin signaling pathway activators GSK3A, GSK3B, WNT1 KDM4E 3614/4885HTT 2026/4885CTNNB1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.